vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and UNIVERSAL DISPLAY CORP \PA\ (OLED). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $142.2M, roughly 1.7× UNIVERSAL DISPLAY CORP \PA\). UNIVERSAL DISPLAY CORP \PA\ runs the higher net margin — 25.2% vs 11.1%, a 14.1% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs -14.5%). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs -5.3%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Universal Display Corporation is a developer and manufacturer of organic light emitting diode (OLED) technologies and materials, and it is a provider of services to the display and lighting industries.
ANIP vs OLED — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $142.2M |
| Net Profit | $27.5M | $35.9M |
| Gross Margin | — | 74.6% |
| Operating Margin | 14.1% | 30.1% |
| Net Margin | 11.1% | 25.2% |
| Revenue YoY | 29.6% | -14.5% |
| Net Profit YoY | 367.5% | -44.3% |
| EPS (diluted) | $1.14 | $0.76 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $142.2M | ||
| Q4 25 | $247.1M | $172.9M | ||
| Q3 25 | $227.8M | $139.6M | ||
| Q2 25 | $211.4M | $171.8M | ||
| Q1 25 | $197.1M | $166.3M | ||
| Q4 24 | $190.6M | $162.3M | ||
| Q3 24 | $148.3M | $161.6M | ||
| Q2 24 | $138.0M | $158.5M |
| Q1 26 | — | $35.9M | ||
| Q4 25 | $27.5M | $66.3M | ||
| Q3 25 | $26.6M | $44.0M | ||
| Q2 25 | $8.5M | $67.3M | ||
| Q1 25 | $15.7M | $64.4M | ||
| Q4 24 | $-10.3M | $46.0M | ||
| Q3 24 | $-24.2M | $66.9M | ||
| Q2 24 | $-2.3M | $52.3M |
| Q1 26 | — | 74.6% | ||
| Q4 25 | — | 76.1% | ||
| Q3 25 | — | 74.6% | ||
| Q2 25 | — | 77.2% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 77.0% | ||
| Q3 24 | — | 77.8% | ||
| Q2 24 | — | 75.8% |
| Q1 26 | — | 30.1% | ||
| Q4 25 | 14.1% | 38.9% | ||
| Q3 25 | 15.9% | 30.9% | ||
| Q2 25 | 6.6% | 39.9% | ||
| Q1 25 | 13.3% | 41.9% | ||
| Q4 24 | -2.3% | 32.3% | ||
| Q3 24 | -13.8% | 41.5% | ||
| Q2 24 | 3.7% | 35.6% |
| Q1 26 | — | 25.2% | ||
| Q4 25 | 11.1% | 38.4% | ||
| Q3 25 | 11.7% | 31.5% | ||
| Q2 25 | 4.0% | 39.2% | ||
| Q1 25 | 8.0% | 38.8% | ||
| Q4 24 | -5.4% | 28.4% | ||
| Q3 24 | -16.3% | 41.4% | ||
| Q2 24 | -1.7% | 33.0% |
| Q1 26 | — | $0.76 | ||
| Q4 25 | $1.14 | $1.40 | ||
| Q3 25 | $1.13 | $0.92 | ||
| Q2 25 | $0.36 | $1.41 | ||
| Q1 25 | $0.69 | $1.35 | ||
| Q4 24 | $-0.45 | $0.96 | ||
| Q3 24 | $-1.27 | $1.40 | ||
| Q2 24 | $-0.14 | $1.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $516.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | — |
| Total Assets | $1.4B | $1.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $516.4M | ||
| Q4 25 | $285.6M | $602.4M | ||
| Q3 25 | $262.6M | $603.0M | ||
| Q2 25 | $217.8M | $525.2M | ||
| Q1 25 | $149.8M | $571.3M | ||
| Q4 24 | $144.9M | $492.7M | ||
| Q3 24 | $145.0M | $551.6M | ||
| Q2 24 | $240.1M | $530.5M |
| Q1 26 | — | — | ||
| Q4 25 | $540.7M | $1.8B | ||
| Q3 25 | $505.8M | $1.7B | ||
| Q2 25 | $436.8M | $1.7B | ||
| Q1 25 | $418.6M | $1.7B | ||
| Q4 24 | $403.7M | $1.6B | ||
| Q3 24 | $405.9M | $1.6B | ||
| Q2 24 | $455.8M | $1.5B |
| Q1 26 | — | $1.9B | ||
| Q4 25 | $1.4B | $2.0B | ||
| Q3 25 | $1.4B | $1.9B | ||
| Q2 25 | $1.3B | $1.9B | ||
| Q1 25 | $1.3B | $1.9B | ||
| Q4 24 | $1.3B | $1.8B | ||
| Q3 24 | $1.3B | $1.8B | ||
| Q2 24 | $920.8M | $1.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $108.9M |
| Free Cash FlowOCF − Capex | $29.1M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 0.5% | — |
| Cash ConversionOCF / Net Profit | 1.10× | 3.03× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $108.9M | ||
| Q4 25 | $30.4M | $31.1M | ||
| Q3 25 | $44.1M | $97.2M | ||
| Q2 25 | $75.8M | $51.9M | ||
| Q1 25 | $35.0M | $30.6M | ||
| Q4 24 | $15.9M | $34.7M | ||
| Q3 24 | $12.5M | $79.9M | ||
| Q2 24 | $17.4M | $67.0M |
| Q1 26 | — | — | ||
| Q4 25 | $29.1M | $15.1M | ||
| Q3 25 | $38.0M | $84.3M | ||
| Q2 25 | $71.8M | $37.5M | ||
| Q1 25 | $32.5M | $17.5M | ||
| Q4 24 | $13.5M | $22.0M | ||
| Q3 24 | $7.7M | $66.2M | ||
| Q2 24 | $13.0M | $57.9M |
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | 8.7% | ||
| Q3 25 | 16.7% | 60.4% | ||
| Q2 25 | 34.0% | 21.8% | ||
| Q1 25 | 16.5% | 10.5% | ||
| Q4 24 | 7.1% | 13.6% | ||
| Q3 24 | 5.2% | 41.0% | ||
| Q2 24 | 9.4% | 36.5% |
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | 9.3% | ||
| Q3 25 | 2.7% | 9.2% | ||
| Q2 25 | 1.9% | 8.4% | ||
| Q1 25 | 1.3% | 7.9% | ||
| Q4 24 | 1.3% | 7.8% | ||
| Q3 24 | 3.2% | 8.4% | ||
| Q2 24 | 3.2% | 5.8% |
| Q1 26 | — | 3.03× | ||
| Q4 25 | 1.10× | 0.47× | ||
| Q3 25 | 1.66× | 2.21× | ||
| Q2 25 | 8.87× | 0.77× | ||
| Q1 25 | 2.23× | 0.47× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | 1.19× | ||
| Q2 24 | — | 1.28× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
OLED
| Material sales | $83.7M | 59% |
| Royalty and license fees | $54.2M | 38% |
| Contract research services | $4.3M | 3% |
